Vijayagopal P, Srinivasan S R, Jones K M, Radhakrishnamurthy B, Berenson G S
Department of Medicine, Louisiana State University Medical Center, New Orleans 70112.
Biochim Biophys Acta. 1988 May 22;960(2):210-9. doi: 10.1016/0005-2760(88)90066-5.
Earlier, we (Vijayagopal, P., et al. (1985) Biochim. Biophys. Acta 837-251) have shown that complexes of plasma low-density lipoproteins (LDL) and arterial chondroitin sulfate-dermatan sulfate proteoglycan aggregate promote LDL degradation and cholesteryl ester accumulation in mouse peritoneal macrophages. Further studies were conducted to determine whether LDL-proteoglycan complex is metabolized by a receptor-mediated process. Native proteoglycan aggregate was isolated from bovine aorta by associative CsCl isopycnic centrifugation. Complex of 125I-labeled LDL and proteoglycan aggregate formed in the presence of 30 mM Ca2+ was incubated with macrophages, and the binding at 4 degrees C and degradation at 37 degrees C of 125I-labeled LDL in the complex was monitored. Both binding and degradation of the complex were specific and saturable, suggesting that the processes are receptor mediated. The Kd for binding was 23 micrograms LDL protein per ml in the complex. Degradation of 125I-labeled LDL-proteoglycan complex was not suppressed by preincubation of macrophages with excess unlabeled complex, suggesting that the receptor for the complex is not subject to down regulation. Both binding and degradation of the complex and the resultant stimulation of cholesteryl ester synthesis were inhibited by limited treatment of cells with low doses of trypsin and pronase, indicating that the binding sites are protein or glycoprotein in nature. Binding was not inhibited by an excess of native LDL and beta-VLDL and exhibited only partial competition by excess unlabeled acetyl-LDL; however, polyinosinic acid, fucoidin and dextran sulfate, known inhibitors of acetyl-LDL binding and degradation in macrophages, did not affect LDL-proteoglycan complex binding and degradation. Similarly, excess unlabeled LDL-proteoglycan complex produced only partial inhibition of the binding and degradation of 125I-labeled acetyl-LDL by macrophages, suggesting that the binding sites for acetyl-LDL and LDL-proteoglycan complex are probably not identical. These studies provide evidence for a receptor-mediated pathway for the metabolism of LDL-proteoglycan complex in macrophages.
早些时候,我们(Vijayagopal, P.等人,(1985)《生物化学与生物物理学报》837 - 251)已经表明,血浆低密度脂蛋白(LDL)与动脉硫酸软骨素 - 硫酸皮肤素蛋白聚糖聚集体的复合物可促进小鼠腹腔巨噬细胞中LDL的降解和胆固醇酯的积累。我们进一步开展研究以确定LDL - 蛋白聚糖复合物是否通过受体介导的过程进行代谢。通过结合性CsCl等密度离心从牛主动脉中分离出天然蛋白聚糖聚集体。将在30 mM Ca2+存在下形成的125I标记的LDL与蛋白聚糖聚集体的复合物与巨噬细胞一起孵育,并监测复合物中125I标记的LDL在4℃下的结合情况以及在37℃下的降解情况。复合物的结合和降解都是特异性的且可饱和的,这表明这些过程是由受体介导的。复合物中结合的解离常数(Kd)为每毫升23微克LDL蛋白。用过量未标记的复合物对巨噬细胞进行预孵育并不能抑制125I标记的LDL - 蛋白聚糖复合物的降解,这表明该复合物的受体不会发生下调。低剂量的胰蛋白酶和链霉蛋白酶对细胞进行有限处理会抑制复合物的结合、降解以及由此引发的胆固醇酯合成的刺激作用,这表明结合位点本质上是蛋白质或糖蛋白。过量的天然LDL和β - VLDL不会抑制结合,过量未标记的乙酰化LDL仅表现出部分竞争作用;然而,已知的巨噬细胞中乙酰化LDL结合和降解的抑制剂多聚肌苷酸、岩藻依聚糖和硫酸葡聚糖并不影响LDL - 蛋白聚糖复合物的结合和降解。同样,过量未标记的LDL - 蛋白聚糖复合物仅对巨噬细胞结合和降解125I标记的乙酰化LDL产生部分抑制作用,这表明乙酰化LDL和LDL - 蛋白聚糖复合物的结合位点可能不相同。这些研究为巨噬细胞中LDL - 蛋白聚糖复合物代谢的受体介导途径提供了证据。